Live

pharmaceutical market

2 articles

Eli Lilly's $3B China Bet: Securing GLP-1 Dominance in World's Largest Metabolic Market

Investing.com

Investing.com·Mar 13·Jeffrey Neal Johnson

Eli Lilly's $3B China Bet: Securing GLP-1 Dominance in World's Largest Metabolic Market

Eli Lilly commits $3 billion to decade-long China expansion, targeting 141 million diabetics and 600 million overweight adults amid intense domestic competition.

LLYNVOsupply chainGLP-1 drugs

GLP-1 Drug Market Poised to Triple to $202B by 2033 Amid Obesity Surge

GlobeNewswire Inc.

GlobeNewswire Inc.·Mar 5·Researchandmarkets.Com

GLP-1 Drug Market Poised to Triple to $202B by 2033 Amid Obesity Surge

Global GLP-1 receptor agonist market projected to grow from $70B in 2025 to $202B by 2033 at 12.78% annual rate, driven by obesity and diabetes prevalence.

LLYSNYNVOAZNIVBIYclinical trialsmarket growth